Clinical trials: Arts
HIV Infections
Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug that belongs to a new class of drugs, called C-C chemokine receptor type 5 (CCR5) receptor blockers.
- Trial name
- VICTOR-E1 (NCT00243230)
- Testing
- Vicriviroc 30 mg, Vicriviroc 20 mg, Background ART Regimen
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
AIDS, AIDS Vaccines
Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects
The purpose of this study is to investigate a combined set of parameters deemed to impact the quality of CMI analyses in terms of the proportion of viable lymphocytes in antiretroviral therapy-naïve HIV-1 infected subjects.
- Trial name
- NCT01610427
- Testing
- Blood sample collection
- Where
- Belgium
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Infection, Human Immunodeficiency Virus
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
This 96 week, Phase 2b study in 150 HIV-1 infected antiretroviral (ART) naive adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of open-label…
- Trial name
- SIGNET (NCT01231555)
- Testing
- GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Efavirenz 600 mg once daily
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- ViiV Healthcare
HIV
Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection
The purpose of this study is to evaluate the protective effect of VAC-3S in controlled HIV patients receiving standard of care antiretroviral treatment.
- Trial name
- NCT02041247
- Testing
- VAC-3S
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 90 people
- Sponsor
- InnaVirVax
HIV-1-infection
The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients
This is a Phase II, randomized, open-label, multi-center, active-controlled study to assess the safety, tolerability, and efficacy of UB-421 administered as an add-on to the standard ART in ART-treated HIV-1 subjects with stably…
- Trial name
- HIV-1 (NCT04404049)
- Testing
- UB-421(25 mg/kg) Q2W, UB-421(25 mg/kg) Q4W
- Volunteers
- 39 people
- Sponsor
- UBP Greater China (Shanghai) Co., Ltd
Infertility (IVF Patients)
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
The goal of this multicenter, randomized, placebo-controlled, double-blind clinical trial is toto evaluate the efficacy and safety of a human menopausal gonadotropin (hMG) in the development of multiple follicles, pregnancy, and…
- Trial name
- GRACE (NCT07216742)
- Testing
- hMG subcutaneous injection
- Where
- 16 sites in United States
- Volunteers
- 659 people
- Sponsor
- Granata Bio Corporation
Depression in Adolescence, Anxiety
Application for Arts-Based Social Prescribing
The goal of this clinical trial is to learn if a personalized arts-based social prescribing program, Art Pharmacy, delivered through a mobile app (SocialRx App) can improve mental health and social connectedness in adolescents…
- Conditions
- Depression in Adolescence, Anxiety, Loneliness, Social Connectedness
- Trial name
- NCT07593443
- Testing
- Art Pharmacy, Stable treatment
- Volunteers
- 230 people
- Sponsor
- SocialRx Inc
Knee Osteoarthritis
Study to Evaluate the Digestive Tolerability of ART44 Versus ART®50 in Patients With Osteoarthritis of the Knee
The primary objective of this study, comparing ART 44 to ART 50, will be the evaluation of digestive tolerability (and in particular of diarrhoea).
- Trial name
- NCT01009671
- Testing
- ART 44, ART 50
- Volunteers
- 210 people
- Sponsor
- Laboratoires NEGMA
HIV-1-infection, HIV Infections
Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV
This study is a phase II, multicenter, randomized, blind, placebo-controlled to evaluate the safety, tolerance, efficacy of ASC22 injection in combination with anti-retroviral therapy to treat subjects living with human…
- Conditions
- HIV-1-infection, HIV Infections, PD-L1 Gene Mutation
- Trial name
- NCT05330143
- Testing
- ASC22 1mg/kg, ASC22 2.5mg/kg, Antiretroviral Therapy
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
HIV, HIV Infections
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
The study aims at evaluating the maintenance of virologic suppression of dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC) at Week 48 post-switch from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in…
- Trial name
- EYEWITNESS (NCT05911360)
- Testing
- DTG/3TC
- Where
- 56 sites in United States, Austria and 10 more
- Volunteers
- 205 people
- Sponsor
- ViiV Healthcare
Infertility
Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice Forielle
This is a multicenter, prospective randomized controlled, interventional investigation to assess the safety and clinical performance of Forielle, a medical device for endometrial washing, in restoring favorable endometrial…
- Trial name
- ENDOMEDE (NCT03387059)
- Testing
- Forielle
- Where
- 7 sites in Italy
- Volunteers
- 9 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Subarachnoid Hemorrhage
Efficacy and Safety Assessment for a New UV-protected Pump Infusion Line in Intravenous Infusion Therapy
To verify the efficacy and safety of Original Perfusor Line (Art.No.8723017) in infusion therapy in Patients with light sensitive drug infusion.
- Trial name
- NCT04309708
- Testing
- Nimodipine pump infusion
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- B. Braun Medical International Trading Company Ltd.
Infertile Women Undergoing Assisted Reproductive Technology (ART)
A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation
To demonstrate the comparative safety and efficacy of Cetrotide® 3 milligram (mg) and Antagon™ in the inhibition of a premature luteinizing hormone (LH) surge in women undergoing ovarian stimulation with recombinant human…
- Trial name
- NCT00298025
- Testing
- Cetrotide®, Antagon ™, Recombinant human follicle stimulating hormone (r-hFSH)
- Volunteers
- 185 people
- Sponsor
- EMD Serono
Stress Reduction, Psychological Wellbeing
The Concert Therapy Pilot Study for Stress Reduction and Wellbeing
The Concert Therapy is an arts-based, pilot interventional study designed to explore the effects of live music, guided breathing, and movement on stress reduction and overall wellbeing.
- Conditions
- Stress Reduction, Psychological Wellbeing, Mental Health, Music Therapy
- Trial name
- TCT (NCT07236918)
- Testing
- The Concert Therapy
- Where
- United Kingdom
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- BeHnam KhodaRahmi
Human Immunodeficiency Virus (HIV)-1 Infection
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
To assess the safety of 48 weeks of treatment with 10 milligrams (mg) of elvucitabine in combination with background antiretroviral therapy (ART) in participants who completed Study ACH443-014A and meet the inclusion and…
- Trial name
- NCT00380159
- Testing
- Elvucitabine, Lamivudine, Emtricitabine
- Where
- 7 sites in United States, Dominican Republic and 2 more
- Volunteers
- 4 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV Infections
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and…
- Trial name
- ENTRANCE (NCT07053384)
- Testing
- VH3810109, Fostemsavir (FTR), SOC INSTI-based ART
- Where
- 41 sites in United States, Belgium and 4 more
- Volunteers
- 107 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on…
- Trial name
- NCT07650916
- Testing
- CAB ULA, RPV ULA, CAB LA
- Where
- 108 sites in United States, Argentina and 8 more
- Volunteers
- 564 people
- Sponsor
- ViiV Healthcare
Infertility, Ovarian Stimulation
A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies
In-vitro fertilization (IVF) of human oocytes followed by the replacement of embryo in the uterine cavity has become a well established treatment for female infertility attributable to damaged fallopian tubes, endometriosis or…
- Trial name
- NCT01121991
- Testing
- Recombinant Human-Luteinizing Hormone (Luveris)
- Volunteers
- 55 people
- Sponsor
- EMD Serono
HIV-1 Infection
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
During the course of HIV infection the number of CD4 cells decreases, resulting in a reduced immunological response and eventually immune deficiency.
- Trial name
- Re-boost (NCT01712256)
- Testing
- Vacc-4x
- Where
- 10 sites in United States, Germany and 3 more
- Volunteers
- 33 people
- Sponsor
- Bionor Immuno AS
Infertility
A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime® of Gemabiotech S.A., Versus Gonal-f ® of Merck Serono, in Patients With Infertility Undergoing ART
This is an open-label, Phase 3, randomized, two arms, multicenter, prospective, experimental study of Folitime® (a new biosimilar formulation of r-hFSH, follitropin alfa) versus the original one (Gonal-f ®).
- Trial name
- NCT02454556
- Testing
- FOLITIME®, Gonal-F®
- Where
- Argentina
- Volunteers
- 106 people
- Sponsor
- Gema Biotech S.A.